Journal article
Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma
Bone marrow transplantation (Basingstoke), Vol.29(7), pp.615-620
2002
DOI: 10.1038/sj.bmt.1703426
PMID: 11979313
Abstract
Fifty-two patients with refractory lymphoma were prospectively treated with prophylactic T lymphocyte infusion after T cell-depleted allogeneic bone marrow transplantation, to induce graft-versus-lymphoma effect. Thirty-three patients had related donors; 19 had unrelated donors. After transplantation with marrow that had 0.8 ± 0.4 × 105CD3+ cells/kg, T cells up to 1.75 × 106 CD3+ cells/kg were given over 3 months provided ⩾ grade II acute graft-versus-host disease (GVHD) was not seen. The cumulative incidence of grades II–IV acute GVHD was 69%. Twenty of 32 evaluable patients (63%) developed chronic GVHD. Ten patients (19%) died of GVHD. The Kaplan–Meier 5-year overall survival of all patients was 34%. On multivariate analyses, chronic GVHD was significant for relapse (hazard ratio of 1.7, P < 0.05), and for overall survival (hazard ratio 1.4, P < 0.001). Chemosensitivity was significant for relapse only on univariate analysis. Patients who developed chronic GVHD had 4 years median survival, compared with 9 months in patients without chronic GVHD, P < 0.001. The study shows that patients with chronic GVHD have superior survivals, most probably related to a graft-versus-lymphoma effect, which could be modulated by prophylactic T cell infusion.
Details
- Title: Subtitle
- Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma
- Creators
- C.-K LEE - Department of Internal Medicine, Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa. College of Medicine, Iowa City, IA, United StatesM DE MAGALHAES-SILVERMAN - Department of Internal Medicine, Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa. College of Medicine, Iowa City, IA, United StatesR. J HOHL - Department of Internal Medicine, Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa. College of Medicine, Iowa City, IA, United StatesM HAYASHI - Department of Internal Medicine, Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa. College of Medicine, Iowa City, IA, United StatesJ BUATTI - Division of Radiation Oncology, Department of Radiology, University of Iowa, College of Medicine, Iowa City, IA, United StatesB. C WEN - Department of Radiation Oncology, University of Miami, Miami, FL, United StatesA SCHLUETER - Department of Pathology, University of Iowa, College of Medicine, Iowa City, IA, United StatesR. G STRAUSS - Department of Pathology and Pediatrics, University of Iowa, College of Medicine, Iowa City, IA, United StatesR. D GINGRICH - Department of Internal Medicine, Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa. College of Medicine, Iowa City, IA, United States
- Resource Type
- Journal article
- Publication Details
- Bone marrow transplantation (Basingstoke), Vol.29(7), pp.615-620
- Publisher
- Nature Publishing Group; Basingstoke
- DOI
- 10.1038/sj.bmt.1703426
- PMID
- 11979313
- ISSN
- 0268-3369
- eISSN
- 1476-5365
- Language
- English
- Date published
- 2002
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Stead Family Department of Pediatrics; Pathology; Radiation Oncology; Neurosurgery; Otolaryngology; Internal Medicine
- Record Identifier
- 9984040267502771
Metrics
20 Record Views